This month’s roundup of new equipment, materials, digital solutions and other news includes items from Lonza, Waters, Eversana, Clinical Ink, and more.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
Leaders from the supply chain solutions company share their thoughts on challenges associated with virtual and hybrid trials, and the COVID-19 pandemic.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
An expert from FourKites shares impacts of the February storm that hit Texas and other parts of North America, and lessons can be learned from the event.
A leader from the global CRO discusses how putting the patient first in clinical research is essential to discovering new therapies for orphan diseases.
Especially with the COVID-19 pandemic impacting studies, the company says, putting patients at the center of studies and trial tech must be top priority.
A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
This month’s hires, promotions, acquisitions and other notable news includes Ajinomoto, Medable, Charles River, Immunai, AstraZeneca and other top firms.
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
According to a Veeva Systems survey, contract research organizations are working to ensure clinical trials keep going during the COVID-19 era and beyond.
An expert speaking at the April 6 Clinical Development Innovations event will discuss an app that matches patients with clinical research opportunities.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
A US court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.
Two experts from CRO Phastar talk about how trial professionals face new, ever-changing challenges regarding collecting and disseminating patient data.
The company’s Patient Advisory Council brings together a range of people and perspectives to help ensure increased diversity, inclusivity and engagement.
The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.
Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.
A new report from the organization forecasts a wave of pharma innovation over the next four years could lead to 75 FDA drug approvals annually by 2025.
The results of a recent Phase III study show caregivers can gauge by individual age, functional status to adapt treatment approaches to specific patients.
The companies are joining on a hybrid clinical trial to test a potential COVID-19 treatment, featuring an ambitious remote patient monitoring strategy.
As the vaccine goes into the arms of more people around the country, the US agency keeps on top of issues around the virus, offering resources and guidance.
Saama’s range of Smart applications will be integrated with the Oracle Health Sciences Clinical One platform to help users accelerate drug development.
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90 countries.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
